EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test

Lei Chen, Jun Liu, Mengcheng Long, Pinghai Hu iD

Technology in Cancer Research & Treatment · 2026-03 · 25

DOI: 10.1177/15330338261435022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 23.03.2026. Verfasst von Lei Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Biomarkers, Tumor. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the General Surgical Key Clinical Specialty Department (Department of Hepatopancreatobiliary Surgery) of The First People’s Hospital of Yunnan Province Platfor….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatocellular carcinoma (HCC) screening in patients with hepatic cirrhosis (HC) relies on ultrasound and alpha-fetoprotein (US + AFP), which has limitations in sensitivity, particularly for early-stage HCC detection. This study aims to evaluate the performance of a novel multi-omics blood test, HCCscreen, with its individual components (methylation, AFP, Des-γ-Carboxy Prothrombin (DCP), mutations) and the standard US + AFP for HCC screening in a hepatic cirrhotic population.

Methods

A total of 5078 patients with known high-risk for HCC were recruited. A prospective screening study was conducted on 650 patients with hepatic cirrhosis identified by ultrasound. Blood samples were collected from all patients before the confirmation of diagnosis by imaging and/or pathological examinations. The performance of HCCscreen, individual markers and US + AFP were calculated and compared. Statistics was performed with Graphpad Prism 5.0.

Results

HCCscreen exhibited a sensitivity of 86.3% at a specificity of 81.3%, with a positive predictive value (PPV) of 28.2% and a negative predictive value (NPV) of 98.6%. The positive likelihood ratio (LR+) was 4.61 and the negative LR (LR-) was 0.17. The positive detection rate (PDR) for all markers increased with more advanced HCC stages, whether Barcelona Clinic Liver Cancer (BCLC) or clinical staging. Among the single-omics, methylation showed the highest PDR, followed by AFP, DCP and mutations. HCCscreen demonstrated superior overall performance with an AUC of 0.87, outperforming individual markers like methylation (AUC = 0.76), AFP (AUC = 0.83), and DCP (AUC = 0.77). Crucially, HCCscreen's PDR was significantly higher than US + AFP in early-stage HCC (BCLC-0 and clinical stage I). Furthermore, while AFP's PDR varied significantly by sex, HCCscreen's performance remained consistent across all demographics. Correlation analysis revealed a significant association only between the HCCscreen score and the methylation score.

Conclusions

The multi-omics approach of HCCscreen significantly enhances early HCC detection in patients with hepatic cirrhosis compared to both its individual components and the current standard of US + AFP. Its robust and consistent performance across patient demographics underscores its potential as a superior tool for population-wide early HCC screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisBiomarkers, TumorHumansFemaleMaleMiddle AgedMultiomicsalpha-FetoproteinsEarly Detection of CancerAgedDNA MethylationROC CurveMutationAdultProthrombinNeoplasm StagingProtein PrecursorsBiomarkers

Stichwörter der Autor:innen

AFPDCPPIVKA-IIcirrhosishepatocellular carcinomamethylationmutationscreening

Substanzen

Biomarkers, Tumoralpha-FetoproteinsacarboxyprothrombinProthrombinProtein PrecursorsBiomarkers

Autor:innen und Institutionen

  • Department of Hepatopancreatobiliary, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.
  • The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.

ORCID-Profile: Pinghai Hu

Förderung

  • the General Surgical Key Clinical Specialty Department (Department of Hepatopancreatobiliary Surgery) of The First People’s Hospital of Yunnan Province Platfor…

Zitieren

APA

Chen, L., Liu, J., Long, M., & Hu, P. (2026). Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261435022

Vancouver

Chen L, Liu J, Long M, Hu P. Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261435022

BibTeX
@article{Chen2026,
  author = {Chen, Lei and Liu, Jun and Long, Mengcheng and Hu, Pinghai},
  title = {Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261435022}
}
Kostenlos starten →